Related Experiment Video
Updated: Feb 19, 2026

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
Published on: January 22, 2019
Novel Latency Reversal Agents for HIV-1 Cure
Adam M Spivak1, Vicente Planelles2
1Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah 84112.
Antiretroviral therapy controls HIV-1 but doesn't cure it due to latent reservoirs. This review explores drugs that reactivate these reservoirs for potential HIV-1 eradication.
Area of Science:
- Immunology
- Virology
- Pharmacology
Background:
- Antiretroviral therapy (ART) manages Human Immunodeficiency Virus Type 1 (HIV-1) infection, transforming it into a chronic condition.
- ART is not curative because of latent HIV-1 proviruses persisting in resting T cells, forming a viral reservoir.
- Eradicating HIV-1 requires targeting and clearing these latently infected cells.
Purpose of the Study:
- To review current pharmacologic strategies for reactivating the latent HIV-1 reservoir.
- To discuss how reactivating latent reservoirs can enable immune targeting and clearance.
- To outline approaches aimed at achieving a curative HIV-1 treatment.
Main Methods:
- Literature review of pharmacologic agents and strategies.
- Analysis of mechanisms for latent HIV-1 reservoir reactivation.
- Examination of immunological approaches for targeting reactivated cells.
Main Results:
- Several pharmacologic approaches are being investigated to induce the expression of latent HIV-1.
- Reactivation aims to make infected cells visible to the immune system for clearance.
- The ultimate goal is to eliminate the viral reservoir and achieve a functional cure for HIV-1.
Conclusions:
- Targeting the latent HIV-1 reservoir is crucial for developing curative therapies.
- Pharmacologic reactivation is a key strategy to enable immune-mediated elimination of the reservoir.
- Further research into these approaches holds promise for achieving HIV-1 eradication.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
07:10Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
Related Concept Videos
Retrovirus Life Cycles
Size and Structure of Viral Genomes
Viruses with RNA Genomes
Retroviruses